Higher severity grade of erlotinib-induced rash is associated with lower skin phototype

Clinical and Experimental Dermatology

Volumn 36, Issue 7, 2011, Pages 733-738

  Luu, M ^a   Boone, S L ^a,b   Patel, J ^a   Sullivan, P ^a   Rademaker, A W ^a   Balagula, Y ^c   Lacouture, M E ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SERIES Clinic   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; MELANIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; RADIOSENSITIVITY; RASH; SKIN PIGMENTATION; ULTRAVIOLET RADIATION;

ADULT; AGED; AGED, 80 AND OVER; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SKIN PIGMENTATION; UNITED STATES;

EID: 80052962819     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04117.x     Document Type: Article

References (25)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32. (Pubitemid 41058344)
2. Lacouture ME., Mechanism of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6 (10): 808-12.
3. El-Abaseri TB, Putta S, Hansen LA,. Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis 2006; 27: 225-31. (Pubitemid 43159873)
4. Peus D, Vasa RA, Meves A, et al. UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival. Photochem Photobiol 2000; 72: 135-40.
5. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151: 238-41. (Pubitemid 39061311)
6. Luu M, Lai SE, Patel J, et al. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 2007; 23: 42-5. (Pubitemid 46189309)
7. Ortonne JP,. Photoprotective properties of skin melanin. Br J Dermatol 2002; 146 (Suppl. 61): 7-10.
8. Kollias N, Sayre RM, Zeise L, et al. Photoprotection by melanin. J Photochem Photobiol B 1991; 9: 135-60.
9. EORTC. RECIST. Available at: (accessed 2 February 2011).
10. National Cancer Institute. Common Terminology Criteria for Adverse Events, v3.0. Available at (accessed 2 February 2011).
11. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913-21. (Pubitemid 47037599)
12. Jost M, Kari C, Rodeck U,. The EGF receptor-an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10: 505-10.
13. Assefa Z, Van Laethem A, Garmyn M, et al. Ultraviolet radiation-induced apoptosis in keratinocytes. on the role of cytosolic factors. Biochim Biophys Acta 2005; 1755: 90-106. (Pubitemid 40982560)
14. Canguilhem B, Pradines A, Baudouin C, et al. RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling. J Biol Chem 2005; 280: 43257-63. (Pubitemid 43049292)
15. Peus D, Hamacher L, Pittelkow MR,. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997; 109: 751-6. (Pubitemid 28053524)
16. Schaffer JV, Bolognia JL,. The melanocortin-1 receptor: red hair and beyond. Arch Dermatol 2001; 137: 1477-85. (Pubitemid 33064243)
17. Bohm M, Wolff I, Scholzen TE, et al. alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem 2005; 280: 5795-802. (Pubitemid 40280060)
18. Scott MC, Wakamatsu K, Ito S, et al. Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J Cell Sci 2002; 115: 2349-55. (Pubitemid 34752978)
19. Yamamoto N, Horiike A, Fujisaka Y, et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2008; 61: 489-96. (Pubitemid 350275984)
20. Erlotinib Package Insert. Available at: (accessed 20 March 2011).
21. Lu JF, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006; 80: 136-45. (Pubitemid 44160689)
22. Chung JH,. The effects of sunlight on the skin of Asians. In: Sun Protection in Man (, Giacomoni P, ed). Amsterdam: Elsevier Science B.V, 2001; 74.
23. Liu W, Lai W, Wang XM, et al. Skin phototyping in a Chinese female population: analysis of four hundred and four cases from four major cities of China. Photodermatol Photoimmunol Photomed 2006; 22: 184-8. (Pubitemid 44088995)
24. Hidalgo M, Bloedow D,. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin Oncol 2003; 30: 25-33. (Pubitemid 36828625)
25. Edgerly M, Fojo T,. Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 2008; 100: 240-2. (Pubitemid 351480535)